Shandong Xinhua Pharma
Shandong Xinhua Pharmaceutical Company Limited, commonly referred to as Xinhua Pharma, is a prominent player in the pharmaceutical industry, headquartered in Shandong, China. Established in 1996, the company has made significant strides in the development and production of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong focus on research and development, Xinhua Pharma has carved out a niche in the production of high-quality generic medications and innovative therapies. The company is recognised for its commitment to quality and compliance with international standards, which has bolstered its market position both domestically and globally. Notable achievements include various certifications and partnerships that enhance its reputation as a reliable supplier in the pharmaceutical sector.
DitchCarbon Score
How does Shandong Xinhua Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shandong Xinhua Pharma's score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shandong Xinhua Pharma's reported carbon emissions
In 2023, Shandong Xinhua Pharma reported total carbon emissions of approximately 260,643,000 kg CO2e, comprising 18,956,000 kg CO2e from Scope 1 and 241,687,000 kg CO2e from Scope 2 emissions. This marks a slight increase from 2022, where total emissions were about 258,468,000 kg CO2e, with Scope 1 emissions at 14,098,000 kg CO2e and Scope 2 emissions at 244,370,000 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The absence of defined reduction targets suggests that while Shandong Xinhua Pharma is aware of its emissions, it may not yet have formalised a comprehensive strategy to address them. Overall, the company's emissions data reflects its operational scale, with revenue increasing from approximately 1,088,000,000 USD in 2022 to about 1,142,000,000 USD in 2023, indicating a potential correlation between revenue growth and emissions levels. As the pharmaceutical industry increasingly focuses on sustainability, Shandong Xinhua Pharma's future climate commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shandong Xinhua Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
